India Pharma

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: ERS Genomics and Aurigene CRISPR/Cas9 License

Lucid Diligence Brief: ERS Genomics’ CRISPR/Cas9 IP license to Aurigene raises…

by Eugenia Tsempera

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Sun Pharma acquisition of Organon

Lucid Diligence Brief: Sun Pharma acquisition of Organon Professional audiences…

by Timos Papagatsias

Biosimilar Landscape in 2024

Navigating the Biosimilar Landscape: What to watch out in 2024 and Beyond

The anticipated expiration of exclusivity rights for major biologics in 2022…

by Ricardo Cardoso

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required
You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.